Rexahn announces IND submission for RX-3117

Rexahn announced that Teva Pharmaceutical Industries has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for RX-3117, a novel oral small molecule chemotherapy agent, under a June 2009 Research and Exclusive License Option Agreement with Teva Pharmaceutical Industries for RX-3117. In August 2012, Rexahn reported the completion of an exploratory Phase I clinical trial of RX-3117 in cancer patients conducted in Europe. The clinical trial demonstrated that RX-3117 is orally bioavailable and no adverse events were reported over the dose range tested. A further Phase I clinical trial in cancer patients is expected to be initiated in the second half of the year.

View Comments (0)